RxDoctor Payments Data

Stephen Connery, MD

Family Medicine · Norman, OKNPI 1184616070

Payments from drug & device makers

$457in general payments, 2019–2025

Across 21 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$124
  • GSK$96
  • Pfizer$77
  • Amgen$48
  • Boehringer Ingelheim$23
  • Insulet Corporation$22
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$38284%
  • Education$7516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$457 in reported general payments places this provider in the 50th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$176,281
Medicare patients
461
Services billed
2,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$115,080
EliquisApixaban51$74,792
JanuviaSitagliptin Phosphate50$70,278
TrulicityDulaglutide54$67,074
MounjaroTirzepatide44$59,926
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$36,267
TymlosAbaloparatide12$31,488
MyrbetriqMirabegron30$27,424
XareltoRivaroxaban13$20,846
Xtampza ErOxycodone Myristate22$19,854
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$19,788
EntrestoSacubitril/Valsartan13$17,428
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$13,044
Atorvastatin Calcium502$9,147
SymbicortBudesonide/Formoterol Fumarate34$8,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$115,080103 claims
PfizerEliquis$77$74,79251 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$96$48,89877 claims
Astellas Pharma US IncMyrbetriq$124$27,42430 claims
Boehringer IngelheimJardiance$23$7,60613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →